168899-38-5

Upstream product

• 7169-06-4 2,3-dimethoxybenzoyl chloride 
• 1447666-95-6 tert-butyl 3-methoxy-2-propylbenzoate 
• 1521-38-6 2,3-dimethoxybenzoic acid 
• 1409654-45-0 tert-butyl 2,3-dimethoxybenzoate 
• 183108-34-1 3-Benzyloxy-2-propyl-benzoic acid methyl ester 
• 183108-33-0 3-Benzyloxy-2-propyl-benzoic acid 
• 183108-32-9 3-benzyloxy-2-n-propylbenzaldehyde 
• 1700-37-4 3-Benzyloxybenzaldehyde 
• 183108-35-2 methyl 3-hydroxy-2-n-propylbenzoate 

Downstream Products

• 1447667-01-7 4-[[3-[3-[5-benzyloxy-2-ethyl-4-(4-fluorophenyl)phenoxy]propoxy]-2-propyl-phenyl]amino]-2,2-dimethyl-4-oxo-butanoic acid 
• 1447666-93-4 4-[[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenyl]amino]-2,2-dimethyl-4-oxo-butanoic acid 
• 1447666-94-5 sodium 4-[[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenyl]amino]-2,2-dimethyl-4-oxo-butanoate 
• 1447694-78-1 methyl propoxybenzoate 
• 1447666-96-7 methyl 3-[3-[5-benzyloxy-2-ethyl-4-(4-fluorophenyl)phenoxy]propoxy]-2-propylbenzoate 
• 1447666-97-8 3-[3-[5-benzyloxy-2-ethyl-4-(4-fluorophenyl)phenoxy]propoxy]-2-propylbenzoic acid 
• 1447666-98-9 3-[3-[5-benzyloxy-2-ethyl-4-(4-fluorophenyl)phenoxy]propoxy]-2-propylbenzamide 
• 1447666-99-0 methyl N-[3-[3-[5-benzyloxy-2-ethyl-4-(4-fluorophenyl)phenoxy]propoxy]-2-propylphenyl]carbamate 
• 1447667-00-6 3-[3-[5-benzyloxy-2-ethyl-4-(4-fluorophenyl)phenoxy]propoxy]-2-propylanilinehydrochloride 
• 183108-35-2 methyl 3-hydroxy-2-n-propylbenzoate 

Relevant academic research and scientific papers

LEUKOTRIENE B4 ANTAGONIST COMPOUND

The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof a

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site

The structure-activity relationship of HIV-1 protease (HIV-1 PR) inhibitors containing AHPBA (3-amino-2-hydroxy-4-phenylbutanoic acid) is discussed. In order to solve the problem of poor oral bioavailability, small-sized dipeptide HIV-1 protease inhibitors containing cyclic urethanes or benzamides at the P2 site were designed and prepared. The substitution patterns of the benzamides contributed significantly to their HIV-1 PR inhibitory activities, and it was shown that the choice of P2-residues was very important. Highly potent inhibitors possessing subnanomolar IC50 values and exhibiting good antiviral potency have been identified. In this class, inhibitor 18 was the most potent (IC90 (CEM/HIV-1 IIIb) 0.11μM) and showed good oral bioavailability in dogs. Copyright (C) 1998 Elsevier Science Ltd.

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Intermediate and process for making

The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.